Results 61 to 70 of about 123,264 (354)

The anti-tumor effect of HDAC inhibition in a human pancreas cancer model is significantly improved by the simultaneous inhibition of cyclooxygenase 2. [PDF]

PLoS ONE, 2013
Pancreatic ductal adenocarcinoma is the fourth leading cause of cancer death worldwide, with no satisfactory treatment to date. In this study, we tested whether the combined inhibition of cyclooxygenase-2 (COX-2) and class I histone deacetylase (HDAC ...
Olivier Peulen, Arnaud Gonzalez, Paul Peixoto, Andrei Turtoi, Denis Mottet, Philippe Delvenne, Vincent Castronovo   +6 more
doaj   +1 more source

Mass-Forming Chronic Pancreatitis: Diagnostic Performance of PET/CT

World Journal of Nuclear Medicine, 2022
Mass-forming chronic pancreatitis and pancreatic ductal adenocarcinoma are most commonly located in the head of pancreas, and there is a marked overlap in clinical features and imaging findings that makes it diagnostically challenging, although prognosis
Ravikanth Reddy
doaj   +1 more source

Imaging for pancreatic ductal adenocarcinoma

Chinese Clinical Oncology, 2017
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers worldwide due to its aggressiveness and the challenge to early diagnosis. Complete surgical resection is the only curative option, but fewer than 20% of patients have potentially resectable disease at the time of the diagnosis.
Davinia Ryan, Natally Horvat, Richard K. G. Do, Maria LaGratta, Pari Shah   +4 more
openaire   +3 more sources

Preclinical models of pancreatic ductal adenocarcinoma [PDF]

The Journal of Pathology, 2015
AbstractPancreatic ductal adenocarcinoma (PDA) is one of the most difficult human malignancies to treat. The 5‐year survival rate of PDA patients is 7% and PDA is predicted to become the second leading cancer‐related cause of death in the USA. Despite intensive efforts, the translation of findings in preclinical studies has been ineffective, due ...
David A. Tuveson, David A. Tuveson, David A. Tuveson, Chang-Il Hwang, Chang-Il Hwang, Hans Clevers, Sylvia F. Boj   +6 more
openaire   +7 more sources

Therapy of pancreatic cancer via an EphA2 receptor-targeted delivery of gemcitabine. [PDF]

, 2016
First line treatment for pancreatic cancer consists of surgical resection, if possible, and a subsequent course of chemotherapy using the nucleoside analogue gemcitabine.
Barile, Elisa, Das, Swadesh K, De, Surya K, Emdad, Luni, Fisher, Paul B, Morvaridi, Susan Kharagh, Pandol, Stephen J, Pellecchia, Maurizio, Quinn, Bridget A, Sarkar, Devanand, Stebbins, John L, Wang, Si   +11 more
core   +2 more sources

The induction of peripheral trained immunity in the pancreas incites anti-tumor activity to control pancreatic cancer progression

Nature Communications, 2022
The advent of immunotherapy has revolutionised cancer therapeutics, but its application in the context of pancreatic ductal adenocarcinoma has been limited.
Anne E. Geller, Rejeena Shrestha, Matthew R. Woeste, Haixun Guo, Xiaoling Hu, Chuanlin Ding, Kalina Andreeva, Julia H. Chariker, Mingqian Zhou, David Tieri, Corey T. Watson, Robert A. Mitchell, Huang-ge Zhang, Yan Li, Robert C. G. Martin II, Eric C. Rouchka, Jun Yan   +16 more
doaj   +1 more source

MicroRNAs in pancreatic ductal adenocarcinoma

World Journal of Gastroenterology, 2011
Ductal adenocarcinoma of the pancreas is a lethal cancer for which the only chance of long-term survival belongs to the patient with localized disease in whom a potentially curative resection can be done. Therefore, biomarkers for early detection and new therapeutic strategies are urgently needed.
Donghwa Kim, Domenico Coppola, Jong Y. Park, James F. Helm, Seung Joon Kim, Mokenge P. Malafa   +5 more
openaire   +3 more sources

Pancreatic ductal adenocarcinoma [PDF]

, 2013
A 61-year-old gentleman who lives with his wife and 20-year-old son, presented to the polyclinic with a four week history of pruritus. On examination he was found to be jaundiced and his LFTs were high.
Bezzina, Sarah, Debattista, Daniel
core  

A Sub-Type of Familial Pancreatic Cancer: Evidence and Implications of Loss-of-Function Polymorphisms in Indoleamine-2,3-Dioxygenase-2. [PDF]

, 2018
BACKGROUND: Variation in an individual\u27s genetic status can impact the development of pancreatic ductal adenocarcinoma; however, the majority of familial pancreatic cancers (FPC) cannot yet be attributed to a specific inherited mutation.
Brody, Jonathan, Cozzitorto, Joseph A., Goetz, Austin, Lavu, Harish, Muller, Alexander J., Nevler, Avinoam, Prendergast, George C., Winter, Jordan M., Yeo, Charles, Yeo, Theresa P.   +9 more
core   +2 more sources

Tumor‐agnostic detection of circulating tumor DNA in patients with advanced pancreatic cancer using targeted DNA methylation sequencing and cell‐free DNA fragmentomics

Molecular Oncology, EarlyView.
We evaluated circulating tumor DNA (ctDNA) detection in advanced pancreatic cancer using DNA methylation, cell‐free DNA fragment lengths, and 5′ end motifs. Machine learning models were trained to estimate ctDNA levels from each feature and their combination.
Morten Lapin, Kjersti Tjensvoll, Karin Hestnes Edland, Satu Oltedal, Herish Garresori, Bjørnar Gilje, Saga Ekedal, Trygve Eftestøl, Jan Terje Kvaløy, Filip Janku, Oddmund Nordgård   +10 more
wiley   +1 more source